Jane Street’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$562K Sell
6,462
-421,183
-98% -$25.4M ﹤0.01% 7729
2026
Q1
$17.2M Buy
427,645
+218,574
+105% +$8.17M ﹤0.01% 1920
2025
Q4
$7.28M Buy
209,071
+204,972
+5,001% +$16.1M ﹤0.01% 2714
2025
Q3
$341K Sell
4,099
-71,716
-95% -$5.19M ﹤0.01% 8665
2025
Q2
$5.56M Buy
+75,815
New +$5.5M ﹤0.01% 2855
2025
Q1
Sell
-133,888
Closed -$8.15M 9568
2024
Q4
$6.75M Buy
133,888
+78,262
+141% +$4.1M ﹤0.01% 2295
2024
Q3
$2.57M Sell
55,626
-88,515
-61% -$3.15M ﹤0.01% 3984
2024
Q2
$4.68M Buy
144,141
+126,207
+704% +$3.46M ﹤0.01% 3058
2024
Q1
$452K Sell
17,934
-73,244
-80% -$1.73M ﹤0.01% 6844
2023
Q4
$2.96M Buy
91,178
+24,102
+36% +$662K ﹤0.01% 3659
2023
Q3
$1.83M Sell
67,076
-27,441
-29% -$794K ﹤0.01% 4206
2023
Q2
$2.1M Buy
94,517
+61,413
+186% +$1.41M ﹤0.01% 4091
2023
Q1
$717K Buy
33,104
+20,409
+161% +$447K ﹤0.01% 5673
2022
Q4
$258K Sell
12,695
-40,028
-76% -$1M ﹤0.01% 7275
2022
Q3
$1.35M Sell
52,723
-15,939
-23% -$427K ﹤0.01% 4890
2022
Q2
$1.63M Sell
68,662
-25,365
-27% -$553K ﹤0.01% 4542
2022
Q1
$2.12M Sell
94,027
-8,451
-8% -$180K ﹤0.01% 4652
2021
Q4
$2.03M Buy
+102,478
New +$2.08M ﹤0.01% 4462
2021
Q3
Sell
-21,744
Closed -$455K 10001
2021
Q2
$478K Buy
+21,744
New +$484K ﹤0.01% 7330
2020
Q4
Sell
-112,052
Closed -$2.36M 7542
2020
Q3
$1.95M Buy
+112,052
New +$1.79M ﹤0.01% 3082
2019
Q4
Sell
-10,207
Closed -$144K 5120
2019
Q3
$144K Buy
+10,207
New +$125K ﹤0.01% 4728
2019
Q2
Sell
-12,240
Closed -$144K 5188
2019
Q1
$144K Sell
12,240
-114,617
-90% -$1.42M ﹤0.01% 4720
2018
Q4
$1.7M Buy
+126,857
New +$1.68M ﹤0.01% 1925
2018
Q1
Sell
-24,960
Closed -$451K 4863
2017
Q4
$451K Sell
24,960
-23,134
-48% -$419K ﹤0.01% 3305
2017
Q3
$928K Buy
+48,094
New +$717K ﹤0.01% 2375
2017
Q2
Sell
-13,933
Closed -$153K 4386
2017
Q1
$153K Buy
+13,933
New +$122K ﹤0.01% 3919

Other funds holding CORT

Jane Street's CORT Position: Q2 2026 in Review

Jane Street reduced its Corcept Therapeutics (CORT) stake by 98% in Q2 2026, selling an estimated $25.4M and leaving 6,462 shares worth $562K. The position accounts for ﹤0.01% of the portfolio, ranked #7729.

Jane Street first reported a position in CORT in Q1 2017 and has held it in 26 quarters since. The position peaked at $17.2M in Q1 2026. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Jane Street held 6,462 shares of Corcept Therapeutics worth $562K as of Q2 2026.
  • Jane Street sold 421,183 Corcept Therapeutics shares in Q2 2026, an estimated $25.4M.
  • Corcept Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #7729 holding.
  • Jane Street first reported a position in Corcept Therapeutics in Q1 2017 and has held it in 26 quarters since.
  • Jane Street's Corcept Therapeutics position peaked at $17.2M in Q1 2026.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.